Benefits
- Analysis of multiple drug classes across several target classes for off-target liabilities
- Enables interpretation of potential toxicity-MOA and selection of superior candidate compounds
- Guides understanding of potential off-target liabilities with broad target class information
- Build knowledgebase with selectivity, potency and toxicity SAR
Leveraging Broad Target Class Profiling to Reveal Off-Target Interactions
More than half of discovery compounds undergo safety-related attrition. Comprehensive profiling against a diverse panel of assays has emerged as an important strategy for identifying potential compound off-target liabilities, while broad selectivity information supports the identification and development of high quality starting points with the best probability of clinical success.
DiscoveRx affords an unprecedented view of global selectivity with the largest commercial panel of kinase and GPCR assays and can identify unanticipated off-target binding, which can be missed using limited assay panels. Combined with additional pharmacological and toxicological data, this annotation provides important information about potential off-target liabilities to better inform compound safety and reduce attrition. Selectivity data is key to support selection of superior candidates with the best chance for success.
Services & Solutions
With several assay formats to choose from, DiscoveRx’s custom profiling service provides a flexible approach for compound profiling.
DiscoveRx offers multiple pre-selected panels run at
regularly scheduled intervals.
From single target HTS to library profiling and follow-up services, DiscoveRx can rapidly and reliably deliver accurate, precise and reproducible data that ensures project timelines are met and maximizes the discovery of potent & selective lead compounds for drug discovery programs.
Convenient outsourced services with consistent high quality data and accelerated turnaround time without the expense of failed experiments and costly capital equipment.